Maze Therapeutics, Inc. (MAZE) Stock
3 of the hedge funds AlphaScala tracks reported MAZE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $27.29M. Company insiders reported 0 open-market buys and 31 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own MAZE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 915K | $27.29M | +194% |
| Citadel Ken Griffin | 853K | $25.44M | +10% |
| D.E. Shaw David Shaw | 12K | $358.6K | -74% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Maze Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Coloma Jason V | Chief Executive Officer | SELL | 2.3K | $68K |
| Nov 2, 26 | Coloma Jason V | Chief Executive Officer | SELL | 336 | $10K |
| Nov 2, 26 | Coloma Jason V | Chief Executive Officer | SELL | 26.6K | $799K |
| Nov 2, 26 | Coloma Jason V | Chief Executive Officer | SELL | 5.3K | $166K |
| Oct 29, 26 | Dandekar Atul | CSBO | SELL | 7.5K | $241K |
| Oct 1, 26 | Coloma Jason V | Chief Executive Officer | SELL | 2.6K | $70K |
| Oct 1, 26 | Coloma Jason V | Chief Executive Officer | SELL | 31.9K | $862K |
| Oct 1, 26 | Bernstein Harold | President, R&D & CMO | SELL | 16.1K | $435K |
| Sep 29, 26 | Dandekar Atul | CSBO | SELL | 7.5K | $203K |
| Sep 4, 26 | Bernstein Harold | President, R&D & CMO | SELL | 9.7K | $255K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →MAZE price chart
Powered by TradingViewWhat does Maze Therapeutics, Inc. do?
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity. The company harnesses human genetics through its Compass platform to identify genetic variants in diseases and link them to biological pathways driving conditions in specific patient populations, a process called variant functionalization. Its lead program, MZE829, is an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in phase II clinical trials for APOL1 kidney disease. MZE782, another oral small molecule inhibitor targeting the solute transporter SLC6A19, is in phase I clinical trials for chronic kidney disease and phenylketonuria. Maze Therapeutics Inc. also advances MZE001 for Pompe disease. Focused on novel precision medicine approaches, it addresses unmet needs in kidney and metabolic disorders. Founded in 2017 and headquartered in South San Francisco, California, Maze Therapeutics Inc. plays a key role in advancing genetically informed therapies in the biopharmaceutical sector.